The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2024:
Thomas Axelsson (Gell Group),
Dharminder Chahal (VanHerk Group),
Peter Elmvik (Stockholms Elbolag),
Tord Lendau (Chairman of the Board).
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 17, 2023.
The Annual General Meeting of SciBase Holding AB (publ) will be held on May 17, 2024 in Stockholm.
Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.
Stockholm, November 2, 2023
SciBase Holding AB (publ)
For more information, please contact: Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, - September 29, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. The study is the first to use Nevisense to measure skin barrier function in human excised skin samples, demonstrating Nevisense as an effective laboratory research device.
Skin barrier research comprises one of the fastest-growing fields within the dermatology community, including the development of new therapeutics, testing cosmetics, and beauty products, testing other consumer goods, and the scientific investigation of diseases related to the skin barrier.
Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of commercially available detergents on the skin barrier of mice and human skin samples. The top-line results of the study indicated that:
EIS is a reliable biomarker/indicator of the skin barrier function in both ex vivo (lab research) and in vivo (human studies) models, with a higher sensitivity than trans-epidermal water loss (TEWL).
EIS showed a significant correlation with protein biomarkers that are associated with inflammatory pathways.
EIS further correlated with the expression of skin barrier-related genes.
EIS is a fast and reliable tool for investigating skin barrier function in both ex vivo and in vivo models, with possible applications in dermatological and cosmetic studies.
"We are very encouraged to see that EIS measurements could identify skin barrier impairment at such an early stage and with high sensitivity. EIS provides an increasingly useful tool for such evaluations" said Professor Cezmi Akdis at SIAF (Swiss Institute of Asthma and Allergy Research).
"This publication represents a rewarding collaborative effort between several leading organizations in the skin barrier research space. We are proud of the technology underpinning the success of this project. Skin barrier research has grown rapidly to include diseases like eczema, psoriasis, allergic disorders, and many others. We believe that Nevisense has the potential to become the state-of-the-art research tool within the skin barrier space, and now we can expand this to include ex vivo, in vivo, and human studies," says Pia Renaudin, appointed Chief Executive Officer of SciBase.
The full results of the study have now been published in the scientific journal Allergy Household laundry detergents disrupt barrier integrity and induce inflammation in mouse and human skin - Rinaldi - Allergy - Wiley Online Library. The study was carried out jointly from SIAF (CH), SciBase (SE), and Genoskin (FR), amongst others.
For more information, please contact: Tord Lendau, Chairman of the Board
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, - September 4, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby announces that Dan Walker has been appointed as VP US Commercial Operations.
Dan was previously Senior Director Commercial Insights, Market Access and Field Reimbursement at Biofrontera Inc., a company focused on the Dermatology market treating actinic keratosis with PDT (Photodynamic Therapy). At Biofrontera Inc., Dan was an instrumental leader in launching the new company in the US market with their first FDA approved drug and device combination product in Dermatology.
With more than 24 years of experience in the US healthcare market, Dan has held leadership roles in Sales, Training, Commercial Operations, Commercial Insights, Key Accounts, Market Access, and Field Reimbursement. His experience building winning teams within the US Dermatology market, and deep knowledge of the US medical benefit reimbursement landscape, will be key in driving SciBase US sales and market access activities forward.
"We see Dan's experience and drive as key in SciBase's success in the US as we expand and build on our recent reimbursement progress with two Medicare Administrative Contractors (MACs). We have recently added employees in both Texas and California to continue to expand within reimbursement and sales. We welcome Dan to the team and look forward to further acceleration of activities in the US market,", says Tord Lendau, Chairman of the Board at SciBase.
For further information visit www.scibase.com or contact:
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, - September 25, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas. Bare Dermatology is a dermatology practice group in the Greater Dallas area, with five offices and a team of nationally renowned dermatologists. The agreement will provide Bare Dermatology with Nevisense, the only FDA-approved test for early melanoma detection at point-of-care.
"At Bare Dermatology, we strive to provide our patients with the highest standard of care. Nevisense can help us to identify melanoma at an early stage, which is critical for improving patient outcomes. Melanoma is a leading cause of death among skin cancers, but when detected early, it has a nearly 100% cure rate. Our patients deserve medical care with the most advanced technology we can provide." said Dr. Aaron Farberg, Chief Medical Officer of Bare Dermatology. Dr. Farberg was recently ranked by his dermatology colleagues in Newsweek Magazine as the #1 medical dermatologist in Texas and #5 in the United States.
"We are excited to together with Bare Dermatology support their efforts to provide the highest quality care to their patients through the use of Nevisense, the only FDA approved melanoma detection technology at point-of-care. SciBase is focused on addressing the need for early melanoma detection in the highest at-risk patient population in the U.S. We are expanding in the areas where melanoma rates are high and where patients have access to the Nevisense test fee schedule from Medical Administrative Contractors (First Coast of Florida and Novitas). We are pleased to collaborate with Bare Dermatology as we expand across the US to address the early detection of melanoma needs", said Pia Renaudin, appointed Chief Executive Officer of SciBase.
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
About Bare Dermatology Bare Dermatology is a comprehensive dermatological medical company headquartered in Dallas, Texas, USA. Their medical practice is dedicated to providing the highest quality clinical care while providing an exceptional patient experience and an uncompromising commitment to employee culture. Their clinicians are world-renowned and are leaders in their fields of expertise. Bare Dermatology was founded on the uncompromising guiding principles of culture, experience, and patient care. https://www.barederm.com/
STOCKHOLM, SWEDEN, - September 28 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the clinical results from a study performed together with the University Children's Hospital Zürich. The study demonstrates the ability of Nevisense to distinguish children with and without Atopic Dermatitis (AD).
Atopic Dermatitis is one of the most prevalent disorders in the world, affecting up to 20% of children globally. Currently, there is no clinical device that can assist in the diagnosis or severity assessment of AD.
The study was performed on children between 4 months and 3 years of age and aimed at identifying children with Atopic Dermatitis with the use of Nevisense. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to create an Augmented Intelligence (AI) algorithm to identify healthy skin from atopic skin, even when measurements were performed on visually unaffected skin. The top-line results of the study indicated that:
Nevisense can detect skin barrier dysfunction in children.
Information about skin barrier dysfunction can be found on visually unaffected skin.
Nevisense complex AI algorithms can be trained to include or disregard certain potential artifacts in the dataset, as exemplified by Age not being an affecting factor.
The study also suggests an ability to predict a child's likelihood of developing AD.
The authors concluded that EIS (Nevisense) can detect skin barrier dysfunction and differentiate skin of children with AD from healthy skin and suggests that EIS may have the ability to predict future AD development.
"For SciBase, these findings underscore our commitment to the skin barrier field, aiming to create products that enhance the prediction and management of childhood Atopic Dermatitis. For additional information regarding our work in this space see: http://investors.scibase.se/en/scibase-announces-collaboration-to-detect-skin-barrier-dysfunction-in-infants ", says Pia Renaudin appointed CEO, SciBase.
The full results of the study have now been published in the scientific journal Allergy and can be found here: https://onlinelibrary.wiley.com/doi/full/10.1111/all.15895. The study was carried out jointly between Children's Hospital Zürich, CKCare and SciBase.
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
